Pubdate: Sat, 14 Jul 2001 Source: New Scientist (UK) Copyright: New Scientist, RBI Limited 2001 Contact: http://www.newscientist.com/ Details: http://www.mapinc.org/media/294 Author: Andy Coghlan NO MORE HIGHS We'll Soon Know If A Vaccine Can Make You Immune To Charlie's Charms TO COKE fiends, it must sound too good to be true-being paid to snort cocaine. And sure enough, there's a catch. The addicts in New York who will soon have this privilege must first take a pioneering vaccine intended to conquer drug addiction. The vaccine, called TA-CD, triggers the production of antibodies against cocaine. The hope is that these antibodies will mop up the drug in the blood before it can trigger the usual "high" in the brain (see New Scientist, 10 June 2000, p 22). This week, Xenova of Slough, Berkshire, was given the go-ahead by the US Food and Drug Administration for the New York trial, in which volunteers who have been vaccinated will be given cocaine. "Patients are not going into this study to quit," admits John St Clair Roberts, the company's medical director. "They're generally going in to be paid." But he points out that if they weren't in the trial they would still be taking the drug. The immune system usually ignores cocaine. To make the body react against it, researchers have bolted cocaine molecules onto the cholera toxin. When the body sees cocaine as part of the combo, it produces antibodies against the drug. Xenova, which acquired the vaccine when it merged with Cantab Pharmaceuticals of Cambridge, this week released results of a preliminary American trial on nine cocaine addicts. After receiving four shots of the vaccine, the addicts produced twice as many anti-cocaine antibodies on average as the 34 volunteers who had taken part in an earlier trial with only three shots. "But we don't know how much antibody you need for the vaccine to be effective," says Roberts. Still, there are anecdotal signs that the vaccine works. When two of the nine volunteers relapsed and took cocaine, they reported there was some attenuation of their "high", says Roberts. "It's all we have to go on at this stage, but it's quite encouraging." The Xenova scientists now need to find out if addicts can override the effects of the antibodies by taking more cocaine than usual. This would be dangerous, as the drug damages the heart. Also, they need to be sure it works against crack cocaine, which acts faster than other forms because it is purer and is inhaled rather than "snorted". Roberts says that addicts would only be given the vaccine during the period it takes to quit. "Most psychiatrists say that after 9 or 10 months, former addicts don't relapse," says Roberts. "In the real world, if you're through that, you're pretty safe." They could receive boosters if they later encounter stresses that make them prone to relapse, he says. But there are signs that the craving may get worse with time. Yavin Shaharn and his colleagues at the National Institute on Drug Abuse in Baltimore looked at craving by seeing how frequently rats pressed a lever that previously gave them cocaine. In this week's Nature (vol 412, p 141), the team reports that the lever-pressing progressively increased over 60 days whenever the rats were reminded of their habit with cues they'd received while on the drug, such as lights and sounds. Roberts says Shaham's study merits attention. - --- MAP posted-by: Jay Bergstrom